Pregabalin for pain in fibromyalgia in adults

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Derry, Sheena ^a   Cording, Malene ^b   Wiffen, Philip J ^a   Law, Simon ^c   Phillips, Tudor ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PREGABALIN;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; CHRONIC PAIN; COCHRANE LIBRARY; DEATH; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FIBROMYALGIA; HUMAN; PAIN ASSESSMENT; PAIN INTENSITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84989162401     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011790.pub2     Document Type: Review

References (109)

1. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. Journal of Pain 2008;9(9):792-805. [CTG: NCT00230776; DOI: 10.1016/j.jpain.2008.03.013]
2. Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Current Medical Research and Opinion 2014;30(10):2069-83. [CTG: NCT01271933; DOI: 10.1185/03007995.2014.928275]
3. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Pregabalin 1008-105 Study Group, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2005;52(4):1264-73. [DOI: 10.1002/art.20983]
4. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136(3):419-31. [DOI: 10.1016/j.pain.2008.02.027]
5. Pauer L, Atkinson G, Murphy TK, Petersel D, Zeiher B. Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin. Clinical Journal of Pain 2012;28(7):609-14. [CTG: NCT00151489; DOI: 10.1097/AJP.0b013e31823dd315]
6. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. Journal of Rheumatology 2008;35(3):502-14. [CTG: NCT00645398]
7. Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care and Research 2014;66(2):293-300. [CTG: NCT01226667; DOI: 10.1002/acr.22111]
8. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Research and Therapy 2012;14(5):R217. [CTG: NCT00830167; DOI: 10.1186/ar4056]
9. A 14-week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia. PhRMA Web Synopsis 7 March 2008.
10. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. Journal of Rheumatology 2011;38(12):2643-52. [CTG: NCT00333866; DOI: 10.3899/jrheum.110569]
11. Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L, Scott G, et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clinical Therapeutics 2012;34(5):1092-102. [DOI: 10.1016/j.clinthera.2012.03.003]
12. Arnold LM, Sarzi-Puttini P, Arsenault P, Khan T, Bhadra Brown P, Clair A, et al. Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo-controlled study. Journal of Rheumatology 2015;42(7):1237-44. [DOI: 10.3899/jrheum.141196]
13. NCT01432236 A phase 3b multicenter, double-blind, randomized, placebo-controlled, 2-way crossover study of pregabalin in the treatment of fibromyalgia with concurrent antidepressant therapy for comorbid depression. clinicaltrials.gov/ct2/show/NCT01432236 (accessed 16 March 2016).
14. Byon W, Ouellet D, Chew M, Ito K, Burger P, Pauer L, et al. Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change. Journal of Clinical Pharmacology 2010;50(7):803-15. [DOI: 10.1177/0091270009352187]
15. Emir B, Murphy TK, Petersel DL, Whalen E. Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert Opinion on Pharmacotherapy 2010;11(14):2275-80. [DOI: 10.1517/14656566.2010.509717]
16. NCT00760474 A double-blind, placebo-controlled cross-over study in fibromyalgia subjects to examine effects of pregabalin on brain response to mechanical pain as assessed by functional magnetic resonance imaging, proton magnetic resonance spectroscopy and subjective ratings. clinicaltrials.gov/ct2/show/NCT00760474 (accessed 16 March 2016).
17. NCT01268631 Mechanism-based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile?. clinicaltrials.gov/ct2/show/NCT01268631 (accessed 16 March 2016).
18. NCT01904097 Study of the brain with optic functional neuroimaging in patients with chronic pain using transcranial direct current stimulation. clinicaltrials.gov/ct2/show/NCT01904097 (accessed 16 March 2016).
19. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Modern Rheumatology/the Japan Rheumatism Association 2013;23(6):1108-15. [DOI: 10.1007/s10165-012-0803-x]
20. Ramzy EA. Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain Practice 2016;Feb 19. [DOI: 10.1111/papr.12409]
21. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care and Research 2012;64(4):597-606. [DOI: 10.1002/acr.21595]
22. Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, Whalen E, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Medicine 2009;10(6):604-10. [DOI: 10.1016/j.sleep.2009.01.009]
23. NCT01387607 A 14-week, randomized, double-blind placebo-controlled study for pregabalin in patients with fibromyalgia. clinicaltrials.gov/ct2/show/NCT01387607 (accessed 16 March 2016). [A0081241]
24. NCT02146430 A randomized, double-blind, placebo- and active-controlled study of DS-5565 for treatment of pain associated with fibromyalgia. clinicaltrials.gov/ct2/show/NCT02146430 (accessed 16 March 2016). [Sponsor ID: DS5565-A-E309]
25. NCT02187159 A randomized, double-blind, placebo- and active-controlled study of DS-5565 for treatment of pain associated with fibromyalgia. clinicaltrials.gov/ct2/show/NCT02187159 (accessed 16 March 2016). [Sponsor ID: DS5565-A-E311]
26. Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, et al. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis and Rheumatism 2013;65(4):1122-8. [DOI: 10.1002/art.37842]
27. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskeletal Disorders 2007;8:27. [DOI: 10.1186/1471-2474-8-27]
28. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics 2010;49(10):661-9. [DOI: 10.2165/11536200-000000000-00000]
29. Bradley LA. Pathophysiology of fibromyalgia. The American Journal of Medicine 2009;122:S22-30. [DOI: 10.1016/j.amjmed.2009.09.008]
30. Choi CJ, Knutsen R, Oda K, Fraser GE, Knutsen SF. The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. Journal of Pain 2010;11:994-1003. [DOI: 10.1016/j.jpain.2010.01.267]
31. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55. [DOI: 10.1001/jama.2014.3266]
32. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1-2):95-7. [DOI: 10.1016/S0304-3959(97)00005-5]
33. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford) 2015;54(2):270-7. [DOI: 10.1093/rheumatology/keu332]
34. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD008244.pub3]
35. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304]
36. Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 2014;312(6):623-30. [DOI: 10.1001/jama.2014.8166]
37. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
38. Eich W, Häuser W, Arnold B, Bernardy K, Brückle W, Eidmann U, et al. Fibromyalgia syndrome. General principles and coordination of clinical care and patient education. Schmerz 2012;26:268-75. [DOI: 10.1007/s00482-012-1167-z]
39. Pregabalin Electronic Medicines Compendium. www.medicines.org.uk/emc/medicine/14651 (accessed 16 March 2016).
40. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research Management 2013;18:119-26. [PUBMED: 23748251]
41. Forseth KO, Husby G, Gran JT, Førre O. Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. Journal of Rheumatology 1999;26:2458-67. [PUBMED: 10555910]
42. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [DOI: 10.1016/j.jclinepi.2011.03.017]
43. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]
44. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]
45. Higgins JPT, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available at www.cochrane-handbook.org.
46. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017]
47. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al. 13. Management of fibromyalgia syndrome - an interdisciplinary evidence-based guideline. German Medical Science 2008;6:Doc 14. [PUBMED: 19675740]
48. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain 2010;11(6):505-21. [DOI: 10.1016/j.jpain.2010.01.002]
49. Häuser W, Kosseva M, Üceyler N, Klose P, Sommer C. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care & Research 2011;63:808-20. [DOI: 10.1002/acr.20328]
50. Häuser W, Galek A, Erbslöh-Möller B, Köllner V, Kühn-Becker H, Langhorst J, et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain 2013;154:1216-23. [DOI: 10.1016/j.pain.2013.03.034]
51. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010292]
52. Häuser W, Henningsen P. Fibromyalgia syndrome - a somaform disorder?. European Journal of Pain 2014;18:1052-9. [DOI: 10.1002/j.1532-2149.2014.00453.x]
53. Häuser W, Ablin J, Fitzcharles MA, Littlejohn G, Luciano JV, Usui C, et al. Fibromyalgia. Nature Reviews Disease Primers 2015;1:Article number: 15022. [DOI: 10.1038/nrdp.2015.22]
54. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: doi.org/10.1016/0197-2456(95)00134-4]
55. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]
56. Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care and Research 2013;65(11):1813-9. [DOI: 10.1002/j.1532-2149.2012.00234.x]
57. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55]
58. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33. [DOI: 10.7326/0003-4819-107-2-224]
59. Lange M, Petermann F. Influence of depression on fibromyalgia: A systematic review. Schmerz 2010;24:326-33. [DOI: 10.1007/s00482-010-0937-8]
60. Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatology International 2012;32:417-26. [DOI: 10.1007/s00296-010-1678-9]
61. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
62. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases 2016;Epub ahead of print. [DOI: 10.1136/annrheumdis-2016-209724]
63. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain 2016;157(1):55-64. [DOI: 10.1097/j.pain.0000000000000314]
64. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-262718-X]
65. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008;135(3):217-20. [DOI: 10.1016/j.pain.2008.01.014]
66. Mills EJ, Ayers D, Chou R, Thorlund K. Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?. Contemporary Clinical Trials 2015;45(Pt A):2-7. [DOI: 10.1016/j.cct.2015.07.019]
67. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
68. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
69. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
70. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]
71. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
72. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013]
73. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]
74. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
75. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
76. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
77. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
78. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
79. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. [DOI: 10.1111/papr.12050]
80. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3]
81. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
82. Moore RA, Wiffen PJ, Eccleston C, Derry S, Baron R, Bell RF, et al. Systematic review of enriched-enrolment randomised-withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain 2015 [Epub]. [DOI: 10.1097/j.pain.0000000000000088]
83. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care & Research 2010;62:611-7. [DOI: 10.1002/acr.20118]
84. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]
85. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154:2310-6. [DOI: 10.1016/j.pain.2013.06.001]
86. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 16 March 2016).
87. Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]
88. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
89. Sommer C, Häuser W, Burgmer M, Engelhardt R, Gerhold K, Petzke F, et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz 2012;26:259-67. [DOI: 10.1007/s00482-012-1174-0]
90. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
91. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150]
92. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49(4):706-15. [DOI: 10.1093/rheumatology/kep432]
93. Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders 2011;12:125. [DOI: 10.1186/1471-2474-12-125]
94. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
95. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 2007;73(2):137-50. [DOI: 10.1016/j.eplepsyres.2006.09.008]
96. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. Journal of Clinical Pharmacology and Therapeutics 2010;35(6):239-56. [DOI: 10.1111/j.1365-2710.2009.01144.x]
97. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
98. Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One 2015;10(9):e0138024. [DOI: 10.1371/journal.pone.0138024]
99. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2]
100. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33(2):160-72. [DOI: 10.1002/art.1780330203]
101. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62(5):600-10. [DOI: 10.1002/acr.20140]
102. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology 2011;38:1113-22. [DOI: 10.3899/jrheum.100594]
103. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain 2013;17(4):581-6. [DOI: 10.1002/j.1532-2149.2012.00234.x]
104. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research 2013;645(5):777-85. [DOI: 10.1002/acr.21931]
105. Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care and Research 2014;66(7):969-71. [DOI: 10.1002/acr.22207]
106. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism 2008;37:339-52. [DOI: 10.1016/j.semarthrit.2007.09.003]
107. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, Schmid A, et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013;136:e247. [DOI: 10.1093/brain/awt053]
108. Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010782]
109. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]